Short Answer:
No, legally you cannot buy Eli Lilly’s Retatrutide in June 2026. Retatrutide is an investigational peptide in Phase 3 clinical trials.
Neither the FDA nor any other major regulatory agency has approved Retatrutide for human consumption yet. According to Eli Lilly, Retatrutide is legally available only through authorized clinical trials.
For research purposes, Retatrutide is available from research peptide suppliers like Orion Peptides. Retatrutide is sold strictly for scientific and research purposes and is not approved for human use.
Summary
| Question | Answer |
| Can you purchase Eli Lilly Retatrutide today? | No, it is not an approved medication for human use directly, but you can buy Retatrutide for research purposes at Orion Peptides |
| Is Retatrutide approved by the FDA? | Not yet |
| In which developmental stage is Retatrutide in 2026 | Phase 3 Clinical Trials |
| Which company has developed Retatrutide? | Eli Lilly and Company |
| What kind of peptide is Retatrutide? | Triple agonist (GLP-1, GIP, Glucagon) |
| Can we purchase research-grade Retatrutide? | Yes, from research peptide suppliers |
| Example of research-grade peptide supplier | Orion Peptides Shop |
Why Can’t You Purchase Eli Lilly Retatrutide Yet?
Retatrutide is popular due to its distinctive triple-agonist activity. The peptide bonds with the following three receptors:
- GLP-1
- GIP
- Glucagon
Although effective results have been found in Phase 3 trials, Retatrutide has yet to go through the full regulatory process. Retatrutide is an investigational drug, and this peptide is only legally available for clinical trials sponsored by Eli Lilly. The company plans to apply for FDA approval sometime later this year, but even in a best-case scenario, it probably won’t be in pharmacies until late 2027 or early 2028.
Retatrutide, as of June 2026, is not currently FDA-approved.
What Is Retatrutide?
Retatrutide (experimental development code LY3437943) is a peptide being developed by Eli Lilly and Company.
It is called a “triple agonist” because it activates all three of these receptors at once:
- GLP-1
- GIP
- Glucagon
This mechanism is of interest to researchers since it permits the investigation of several metabolic pathways in a single compound.
Will Researchers ever get the Retatrutide?
Yes. The Eli Lilly formulation is not currently available for purchase, but a peptide supplier can supply research-grade Retatrutide for laboratory research.
The research will generally assess suppliers based on the following criteria:
- Purity testing
- Certificate of Analysis (COA)
- Third-party testing
- Product availability
- Documentation standards
Orion Peptides Retatrutide Prices (June 2026)
Orion Peptides sells Retatrutide in various concentrations, and the current listed prices include:
- Retatrutide 5 mg: $64
- Retatrutide 10 mg: $95
- Retatrutide 15 mg: $140
- Retatrutide 20 mg: $172
- Retatrutide 30 mg: $390
How Does Retatrutide Compare to Other Research Peptides?
| Peptide | Focus of research |
| Retatrutide | Signaling of GLP-1, GIP, and glucagon receptors |
| Tirzepatide | Signaling of GLP-1 and GIP receptors |
| Semaglutide | Signaling of GLP-1 receptor |
| Cagrilintide | Research related to the Amylin pathway |
| AOD-9604 | GH fragment research |
Frequently Asked Questions
Will Retatrutide be approved by the FDA in 2026?
No. Retatrutide is still in Phase 3 clinical development and has not been approved by the FDA. (Free Medical Journals)
Will Retatrutide be approved by the FDA in 2026?
No. Retatrutide is still in Phase 3 clinical development and has not been approved by the FDA yet. And it may be approved for human use may be late in 2027 or early 2028
Why is Retatrutide a topic of interest nowadays?
Its triple-agonist activity against GLP-1, GIP, and glucagon receptors is a topic of interest for researchers. (PMC)
Click and Learn: What is Eli Lilly Retatrutide? Price and Where to Buy Online?
Final Thoughts
The answer to the question “Can you get Eli Lilly Retatrutide now?” is “no.” Retatrutide is currently a Phase 3 investigational drug and is not yet commercially available as of June 2026. Eli Lilly is stating that the compound is legally available only through its clinical trial programs.
Researchers who need laboratory-grade material can acquire research-use-only Retatrutide from companies like Orion Peptides, which currently offers Retatrutide in various concentrations ranging from 5 to 30 mg at prices ranging from $64 to $390.
Research Use Only Disclaimer
Retatrutide is an experimental drug. Orion Peptides sells its research-grade Retatrutide for laboratory research and/or analytical use only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any kind of disease.
